Claims for Patent: 5,279,823

Summary for Patent: 5,279,823

Title:	Purified forms of DNASE
Abstract:	The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
Inventor(s):	Frenz; John (Millbrae, CA), Shire; Steven J. (Belmont, CA), Sliwkowski; Mary B. (San Carlos, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	07/895,300
Patent Claims:	1. Purified deamidated human DNase. 2. Purified non-deamidated human DNase. 3. A pharmaceutical composition consisting of deamidated human DNase as the active principle and optionally a pharmaceutically acceptable excipient. 4. A pharmaceutical composition consisting of non-deamidated human DNase as the active principle and optionally a pharmaceutically acceptable excipient. 5. A pharmaceutical composition according to claim 4 wherein the excipient is sterile water. 6. A pharmaceutical composition according to claim 4 wherein the excipient is a sterile unbuffered aqueous solution at about pH 4.5-6.8. 7. A pharmaceutical composition according to claim 4 wherein said composition is in an aerosol form. 8. A pharmaceutical composition comprising non-deamidated human DNase that is substantially free of deamidated human DNase that is substantially free of deamidated human DNase.

Details for Patent 5,279,823

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23